GoodRx - Class A opened lower at $3.64, compared with its previous close of $3.65. In the last trading session, the stock traded between $3.47 and $3.64. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in GoodRx - Class A is now worth
$ 8.86
Resulting in a loss of
$ 91.14 (91.14%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
0%
Hold
50%
Sell
50%
Markets Today
Today's Change
$-0.13 (-3.42%)
Day High
$3.64
Day Low
$3.47
Day Open
$3.64
Prev Close
$3.65
Volume
6,04,282
1W Return
-5.19%
1M Return
1.41%
3M Return
-7.11%
6M Return
24.12%
1Y Return
16.34%
Fundamentals
Market Cap ($ Mn)
378
PE Ratio
70.60
PB Ratio
1.85
PEG Ratio
7.11
ROE
4.70%
ROCE
7.42%
EPS (TTM)
$0.03
Investment Returns
1 Week
-5.19%
1 Month
1.41%
3 Months
-7.11%
6 Months
24.12%
9 Months
58.07%
Financials
Quarterly
All values in $ Mn
203.0
Mar 25
203.1
Jun 25
196.0
Sep 25
194.8
Dec 25
194.0
Mar 26
200.4
Jun 26
Updates
10Nov
GoodRx joins Google Cloud Gemini launch to surface prescription savings
GoodRx becomes a launch partner for Google Cloud's Gemini for healthcare. Integration uses Model Context Protocol to surface prescription pricing in AI workflows. Healthcare teams can compare pharmacy prices via natural language queries. Google Cloud is the first deployment partner for GoodRx's MCP integration.
2 days ago
3Nov
GoodRx flags reliance issue on Q1, Q2 2026 financials
GoodRx Holdings Inc declared Q1 and Q2 2026 financials unreliable. Pharma Direct revenue was understated by $29.773 million. Company expects to report a material weakness in internal controls.
10 days ago
5Oct
GoodRx Holdings Q2FY26 Results: Revenue $200.4M, Pharma Direct up 76%
Revenue reached $200.4 million, exceeding expectations. Pharma Direct revenue surged 76% YoY to $61.6 million. Subscription revenue grew 39% YoY to $28.5 million. Full-year revenue guidance raised to $790-$805 million.
GoodRx Holdings Inc. increased its FY2026 sales guidance to $790.000 million-$805.000 million, up from $765.000 million-$785.000 million. The new outlook exceeds the consensus estimate of $775.751 million, reflecting improved business performance expectations.
3mo ago
10Jul
GoodRx sets date for Q2FY26 earnings release
GoodRx Holdings, Inc. announced it will release its Q2FY26 financial results on August 5, 2026, followed by a conference call on August 6, 2026, to discuss performance and business outlook.
